Nikoletta Psatha, Penelope-Georgia Papayanni and Evangelia Yannaki* Pages 364 - 378 ( 15 )
Hemoglobinopathies, including severe β-thalassemia and sickle cell disease, represent the most common monogenic disorders worldwide. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only approved curative option for these syndromes, albeit limited to patients having a suitable donor. Gene therapy, by making use of the patient’s own hematopoietic stem cells to introduce a normal copy of the β-globin gene by viral vectors, bridged the gap between the need for cure of patients with hemoglobinopathies and the lack of a donor, without incurring the immunological risks of allo-HSCT. However, gene therapy for hemoglobinopathies proved a difficult and elusive goal for decades and only recently, lenti-viral vector gene therapy was successfully transferred to the clinic. Importantly, during the last years, additional curative options for patients with thalassemia and sickle cell disease are being developed, based on the ability to manipulate the genome by employing programmable nucleases and next-generation genome-modifying tools, thus providing the exciting prospects of targeted in-situ gene correction. In this review, we will summarize current developments in the new era of treatment for hemoglobinopathies, elaborate on lessons gained from gene therapy trials and discuss the exciting prospects and challenges of genome editing.
Hemoglobinopathies, Thalassemia, Sickle cell anemia, Gene therapy, Genome editing, Hematopoietic stem cells.
Division of Medical Genetics, University of Washington, Seattle, Washington, Gene and Cell Therapy Center, Hematology Department– Hematopoietic Cell Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Division of Medical Genetics, University of Washington, Seattle, Washington